WO2011122869A2 - 쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물을 포함하는 피부 미용용 조성물 - Google Patents
쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물을 포함하는 피부 미용용 조성물 Download PDFInfo
- Publication number
- WO2011122869A2 WO2011122869A2 PCT/KR2011/002218 KR2011002218W WO2011122869A2 WO 2011122869 A2 WO2011122869 A2 WO 2011122869A2 KR 2011002218 W KR2011002218 W KR 2011002218W WO 2011122869 A2 WO2011122869 A2 WO 2011122869A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- cumestrol
- cosmetic composition
- composition
- coumestrol
- Prior art date
Links
- ZZIALNLLNHEQPJ-UHFFFAOYSA-N coumestrol Chemical compound C1=C(O)C=CC2=C1OC(=O)C1=C2OC2=CC(O)=CC=C12 ZZIALNLLNHEQPJ-UHFFFAOYSA-N 0.000 title claims abstract description 182
- 239000000203 mixture Substances 0.000 title claims abstract description 110
- 239000002537 cosmetic Substances 0.000 title claims abstract description 44
- 229940069765 bean extract Drugs 0.000 title abstract 2
- 230000006872 improvement Effects 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 230000037303 wrinkles Effects 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 230000003020 moisturizing effect Effects 0.000 claims description 10
- 230000037394 skin elasticity Effects 0.000 claims description 10
- 230000009759 skin aging Effects 0.000 claims description 9
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 8
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 7
- 206010000496 acne Diseases 0.000 claims description 7
- 235000020712 soy bean extract Nutrition 0.000 claims description 7
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 201000008937 atopic dermatitis Diseases 0.000 claims description 6
- 230000002087 whitening effect Effects 0.000 claims description 6
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 206010040880 Skin irritation Diseases 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 239000003963 antioxidant agent Substances 0.000 claims description 4
- 230000008491 skin homeostasis Effects 0.000 claims description 4
- 230000036556 skin irritation Effects 0.000 claims description 4
- 231100000475 skin irritation Toxicity 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 210000003491 skin Anatomy 0.000 description 63
- 239000004480 active ingredient Substances 0.000 description 24
- 230000000694 effects Effects 0.000 description 21
- 238000012360 testing method Methods 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 15
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 14
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 13
- 239000012091 fetal bovine serum Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 210000004927 skin cell Anatomy 0.000 description 11
- 108010035532 Collagen Proteins 0.000 description 10
- 102000008186 Collagen Human genes 0.000 description 10
- 244000068988 Glycine max Species 0.000 description 10
- 235000010469 Glycine max Nutrition 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 238000011156 evaluation Methods 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 229930014626 natural product Natural products 0.000 description 9
- 239000003642 reactive oxygen metabolite Substances 0.000 description 9
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 230000002407 ATP formation Effects 0.000 description 6
- 206010003645 Atopy Diseases 0.000 description 6
- 201000004624 Dermatitis Diseases 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229960002986 dinoprostone Drugs 0.000 description 6
- 239000012737 fresh medium Substances 0.000 description 6
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 6
- 230000002000 scavenging effect Effects 0.000 description 6
- 230000032683 aging Effects 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 230000036252 glycation Effects 0.000 description 5
- 230000008099 melanin synthesis Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 235000013527 bean curd Nutrition 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000021384 green leafy vegetables Nutrition 0.000 description 4
- 235000008216 herbs Nutrition 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000004040 coloring Methods 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 235000021374 legumes Nutrition 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000036560 skin regeneration Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- PXEZTIWVRVSYOK-UHFFFAOYSA-N 2-(3,6-diacetyloxy-2,7-dichloro-9h-xanthen-9-yl)benzoic acid Chemical compound C1=2C=C(Cl)C(OC(=O)C)=CC=2OC2=CC(OC(C)=O)=C(Cl)C=C2C1C1=CC=CC=C1C(O)=O PXEZTIWVRVSYOK-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 2
- 244000046052 Phaseolus vulgaris Species 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010040829 Skin discolouration Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 244000013123 dwarf bean Species 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 235000021331 green beans Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 2
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 2
- 229940113124 polysorbate 60 Drugs 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 1
- HIYAVKIYRIFSCZ-CYEMHPAKSA-N 5-(methylamino)-2-[[(2S,3R,5R,6S,8R,9R)-3,5,9-trimethyl-2-[(2S)-1-oxo-1-(1H-pyrrol-2-yl)propan-2-yl]-1,7-dioxaspiro[5.5]undecan-8-yl]methyl]-1,3-benzoxazole-4-carboxylic acid Chemical compound O=C([C@@H](C)[C@H]1O[C@@]2([C@@H](C[C@H]1C)C)O[C@@H]([C@@H](CC2)C)CC=1OC2=CC=C(C(=C2N=1)C(O)=O)NC)C1=CC=CN1 HIYAVKIYRIFSCZ-CYEMHPAKSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 240000007124 Brassica oleracea Species 0.000 description 1
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 1
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 1
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 1
- 108010075254 C-Peptide Proteins 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000510678 Falcaria vulgaris Species 0.000 description 1
- 241000555682 Forsythia x intermedia Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 244000299790 Rheum rhabarbarum Species 0.000 description 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 1
- 240000002913 Trifolium pratense Species 0.000 description 1
- 235000015724 Trifolium pratense Nutrition 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000809 air pollutant Substances 0.000 description 1
- 231100001243 air pollutant Toxicity 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- -1 blockers Substances 0.000 description 1
- HIYAVKIYRIFSCZ-UHFFFAOYSA-N calcium ionophore A23187 Natural products N=1C2=C(C(O)=O)C(NC)=CC=C2OC=1CC(C(CC1)C)OC1(C(CC1C)C)OC1C(C)C(=O)C1=CC=CN1 HIYAVKIYRIFSCZ-UHFFFAOYSA-N 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000011382 collagen catabolic process Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229930016834 coumestan Natural products 0.000 description 1
- JBIZUYWOIKFETJ-UHFFFAOYSA-N coumestan Chemical compound O1C2=CC=CC=C2C2=C1C(C=CC=C1)=C1OC2=O JBIZUYWOIKFETJ-UHFFFAOYSA-N 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229930013032 isoflavonoid Natural products 0.000 description 1
- 150000003817 isoflavonoid derivatives Chemical class 0.000 description 1
- 235000012891 isoflavonoids Nutrition 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000003061 melanogenesis Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- GSGDTSDELPUTKU-UHFFFAOYSA-N nonoxybenzene Chemical compound CCCCCCCCCOC1=CC=CC=C1 GSGDTSDELPUTKU-UHFFFAOYSA-N 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- VMSRVIHUFHQIAL-UHFFFAOYSA-M sodium;n,n-dimethylcarbamodithioate Chemical compound [Na+].CN(C)C([S-])=S VMSRVIHUFHQIAL-UHFFFAOYSA-M 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
Definitions
- the present invention relates to a composition for skin care comprising a composition comprising a Kumestrol or a soybean extract comprising Kumestrol.
- One aspect of the present invention is cumestrol; Or to provide a cosmetic composition for skin comprising a soybean extract containing Kumestro as an active ingredient.
- Another aspect of the invention is a cumestrol; Or to provide a cosmetic composition for a cosmetic composition comprising a soybean extract containing Kumestro as an active ingredient.
- Cosmetic composition for skin Kucumrol; Or soybean extract comprising kumestrol as an active ingredient.
- Skin cosmetic composition according to an aspect of the present invention is excellent skin elasticity improvement, skin wrinkle improvement, skin whitening, skin moisturizing, anti-inflammatory, antibacterial, skin aging inhibitory, antioxidant, acne skin improvement, atopic dermatitis improvement, skin irritation relief, It has the effect of maintaining skin homeostasis, alleviating or improving skin allergy, and can be utilized in various fields such as cosmetics and food.
- extract includes any material obtained by extracting a component therefrom from a natural product, regardless of the method of extraction or the kind of the component.
- extract includes all the components which are dissolved in a solvent from a natural product using water or an organic solvent, and those obtained by extracting only a specific component such as an oil such as oil.
- skin refers to a tissue covering the body surface of an animal, and is a broad concept including not only tissues covering the body surface such as the face or body, but also the scalp and hair.
- skin care is a concept that includes not only the beauty of the skin but also all the treatments or treatments to make the skin healthy and lively.
- One aspect of the present invention is cumestrol; Or it provides a skin cosmetic composition comprising a soybean extract containing Kumestro as an active ingredient.
- Cumestrol 3,9-dihydroxy-6H-benzofuro (3,2-c) (1) benzopyran-6-one
- CMS 3,9-dihydroxy-6H-benzofuro (3,2-c)
- benzopyran-6-one has a structure as shown in Formula 1 below.
- Coumestrol is one of the phytoestrogens found primarily in the seeds, roots or leaves of legumes, comositae plants. It is a kind of isoflavonoid that can be classified as a coumestan-based compound and is known to have an estrogen effect.
- the cosmetic composition for skin comprises a kumestrol, or a natural product or extract thereof including the cumestrol.
- natural products including cumestrol include at least one legume selected from soybeans, peas, green beans and germinated soybeans, red shamrock, purple forsythia (alfalfa) or sprout cabbage.
- the natural product comprising cumestrol may be soybean.
- the soybean can be used without particular limitation so long as the legumes containing cumestrol.
- the kind of beans that can be used in the present invention may be varieties for tofu and tofu, for herbs, for rice or for soybeans.
- tofu and tofu Daepoong, Hojang, Jangwon, Rhubarb, Sodam, Songhak, Daewon, Genuine, and protein ), Soy milk, Shinpaldal, Taekwang, Great Wall, Longevity, Wuhan, Baiyun, New Egg, Golden and Long Leaf. .
- Varieties for herbs include mythology, wishes, Anpyeong, southwest, colorful, sorok, soho, vocation, tea garden, and fengshan Herbs, Iksan Herbs, Sobaek Herbs, Gwang'an, Single Leaf, and Galaxy.
- rice varieties include celadon, black blue, black sea flakes, black and white, black soybeans and one black soybeans.
- varieties for green soybeans include Daol, fresh green, birds, black, sorghum green beans, Hwaeum green soybeans, and large greens.
- the soybean is preferably a variety capable of germinating and resistant to pests.
- Such beans include, for example, myths, wishes, Anpyeong, southwest, colorful, sorok, soho, vocation, and tea gardens. ), Pungsan greens, Iksan greens, Sobaek greens, Gwangan, single leaves and galaxies.
- the natural product or extract thereof may comprise a large amount of cumetrol, specifically 0.01 to 50% by weight, more specifically 0.1 to 30% by weight, based on the total weight of the natural product or extract thereof. Can be.
- the extract of the natural product containing cumestrol is completely concentrated after extracting the natural product containing cumestrol in water or ethanol at room temperature or immersed in water and then dispersed again in water, the same amount of hexane , Dichloromethane, chloroform, ethyl acetate, butanol, ethanol, methanol, and water.
- the extraction method is not limited thereto, and any extraction method may be used such that the final extract contains cumestrol.
- the skin cosmetic composition may be a skin cosmetic composition for improving skin elasticity or wrinkle improvement to improve the elasticity of the skin and improve wrinkles.
- Cumestrol which is included in the composition as an active ingredient, inhibits expression of matrix metalloproteinase-I (MMP-1), which may act as collagenase, promotes type I pN collagen synthesis, inhibits skin cell glycosylation, It acts to promote intracellular ATP production.
- MMP-1 matrix metalloproteinase-I
- a composition containing cumestrol as an active ingredient may have an excellent skin elasticity improvement or wrinkle improvement effect.
- the composition is particularly effective in improving skin wrinkles induced by UV.
- the skin cosmetic composition may be a composition for skin whitening.
- Cumestrol which the composition comprises as an active ingredient, significantly cancels free radicals generated by skin aging and ultraviolet irradiation, inhibits melanin production, and inhibits glycation of skin cells. Through this action, a composition containing cumestrol as an active ingredient can have an excellent skin lightening effect.
- the skin cosmetic composition may be a composition for moisturizing the skin.
- Cumestrol which the composition contains as an active ingredient, inhibits skin moisture loss, promotes intracellular ATP production, and has excellent skin regeneration ability. Through this action, the composition containing cumestrol as an active ingredient may have an excellent skin moisturizing effect.
- the skin cosmetic composition may be an anti-inflammatory or antimicrobial composition.
- Cumestrol which the composition comprises as an active ingredient, inhibits prostaglandin E2 (PGE2) production, promotes intracellular ATP production, and cyclooxygenase-2 (COX-) induced by lipopolysacchride (LPS).
- PGE2 prostaglandin E2
- COX- cyclooxygenase-2
- LPS lipopolysacchride
- the composition containing cumestrol as an active ingredient may have excellent anti-inflammatory and antibacterial effect.
- the skin cosmetic composition may be a composition for inhibiting skin aging or antioxidant.
- the skin is subject to oxidative stress by free radicals and free radicals.
- Kumestrol contained in the composition as an active ingredient has an active oxygen scavenging effect, improves skin elasticity and wrinkles, has excellent skin whitening and skin moisturizing effects, and promotes skin cell energy metabolism, thereby inhibiting skin aging. Or antioxidant effects.
- the composition containing cumestrol as an active ingredient may have a skin aging inhibitory or antioxidant effect.
- the skin care composition may be a composition for improving acne skin.
- Cumestrol which the composition contains as an active ingredient, inhibits PGE-2 production and regulates sebum control and inflammation by inhibiting biosynthesis of cyclooxygenase-2 (COX-2) induced by lipopolysaccharide (LPS). It has a regulating effect, thereby improving acne and skin troubles.
- the composition containing cumestrol as an active ingredient may have an acne skin improvement effect.
- the skin cosmetic composition may be a composition for improving atopic skin.
- Kumestrol comprising the composition as an active ingredient has excellent skin moisturizing, anti-inflammatory and antimicrobial effects, and excellent skin cell regeneration ability can improve atopic skin.
- the skin cosmetic composition may be a composition for alleviating skin irritation or maintaining skin homeostasis.
- Kumestrol which the composition comprises as an active ingredient, inhibits PGE-2 production and inhibits biosynthesis of cyclooxygenase-2 (COX-2) induced by lipopolysaccharide (LPS), thereby causing It has the effect of inhibiting skin inflammatory response and damage.
- the composition containing cumestrol as an active ingredient has an effect of alleviating skin irritation caused by various external harmful factors such as chemicals, air pollutants, and ultraviolet rays to protect the skin and maintain skin homeostasis.
- the cosmetic composition for skin may be a composition for alleviating or preventing skin allergy.
- Kumestrol comprising the composition as an active ingredient has excellent skin moisturizing, anti-inflammatory and antibacterial effects, and has excellent skin cell regeneration ability. Therefore, the composition containing cumestrol as an active ingredient may have an effect of alleviating or preventing skin allergy.
- the composition according to one aspect of the present invention comprises a soybean extract comprising 0.001 to 30% by weight, specifically 0.01 to 10% by weight, more specifically 0.1 to 5% by weight of cumestrol or cumestrol relative to the total weight of the composition. can do.
- weight percent not only is it appropriate to exhibit the intended effect of the present invention, but also satisfies both the stability and safety of the composition, it may be appropriate to be included in the above range in terms of cost-effectiveness.
- Skin cosmetic composition according to an aspect of the present invention may be a cosmetic composition.
- the cosmetic composition may comprise a cosmetic or dermatologically acceptable medium or base.
- These are all formulations suitable for topical application, for example emulsions obtained by dispersing the oil phase in solutions, gels, powders, pastes, anhydrous products, water phases, emulsions obtained by dispersing the water phase in oil phases, multiemulsions, suspensions, microemulsions. It may be provided in the form of an aerosol composition containing microcapsules, microgranules, ionic (liposomal) and nonionic vesicle dispersants, foams or compressed propellants. These compositions can be prepared according to conventional methods in the art.
- Cosmetic compositions may include fatty substances, organic solvents, solubilizers, thickeners, gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers , Metal ion sequestrants, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or adjuvants commonly used in the cosmetic or dermatological fields Can be. Such adjuvants are introduced in amounts generally used in the cosmetic or dermatological fields.
- the cosmetic composition is not particularly limited in formulation, and may be appropriately selected in accordance with the desired purpose.
- lotion, lotion, essence, cream, ointment, gel, pack, patch, spray, powder foundation, emulsion foundation, consil stick, hand or foot lotion, hand or foot cream, hand or foot oil, hand or foot It may be prepared in one or more formulations selected from the group consisting of essences, hand or foot cleansers, soaps, cleansing creams, cleansing lotions, cleansing foams and cleansing water, but is not limited thereto.
- Skin cosmetic composition according to an aspect of the present invention may be a food composition.
- the formulation of the food composition is not particularly limited, but may be, for example, formulated into tablets, granules, drinks, caramels and the like.
- the food composition of each formulation may be suitably selected by a person skilled in the art according to the formulation or purpose of use in addition to the active ingredient, and may be synergistic when applied simultaneously with other raw materials.
- the daily dosage of the active ingredient is within the level of those skilled in the art, the daily dosage of which is for example from 0.1 mg / kg / day to 5000 mg / kg / day, more specifically from 50 mg / kg / day to 500 mg / kg / day, but is not limited thereto and may vary depending on various factors such as age, health condition, complications, etc. of the subject to be administered.
- test examples are provided for the purpose of illustration only to help the understanding of the present invention, and the scope and scope of the present invention are not limited thereto.
- DCFH -DA UVB-induced Reactive Oxygen Species
- the amount of ROS in a cell can be evaluated by measuring the fluorescence intensity of the DCFH-DA treated cell.
- Keratinocytes obtained from Dr. Fusenig of the German Cancer Research Center were dispensed in 96 well black plates (Greiner BioOne Inc, NC, USA) at 1 X 10 4 per well and cultured for 24 hours. It was. Thereafter, fresh media without FBS were treated with dilution so that the final concentration of cumestrol was 0.01, 0.1, 1 ⁇ M. After 24 hours of incubation of the test substance and washing with HCSS (HEPES-buffered control salt solution) to remove the remaining medium, 100 ⁇ L of DCFH-DA medium prepared at 20 ⁇ M to HCSS was added, at 37 °C, 5% CO 2 conditions After incubation for 20 minutes, washed with HCSS.
- HCSS HEPEG-buffered control salt solution
- UVB 30 mJ / cm 2 was irradiated with 100 ⁇ l of HCSS. After diluting the same concentration of cumestrol in HCSS was incubated for 3 hours at 37 °C, 5% CO 2 conditions.
- the fluorescence intensity of DCF was measured using a Wallac VICTOR2 Fluorometer (Wallac, Turku, Finland) under conditions of excitation wavelength 485 nm and emission wavelength 530 nm.
- ROS scavenging ability (%) was calculated based on the measured fluorescence intensity and is shown in the following table.
- cumestrol has UVB-induced ROS scavenging efficacy, and the higher the concentration of cumestrol, the higher the efficacy. Therefore, the composition containing cumestrol may inhibit skin oxidation by ultraviolet rays, inhibit photoaging, and exhibit a skin whitening effect.
- human fibroblasts (CAS-C-004-5C, Invitrogen, CA, USA) were dispensed at 1 X 10 4 per well in 24 well-plates. It was incubated for about 24 hours in a medium containing 10% FBS until reaching a confluency of about 80%. Thereafter, the cells were exchanged with a medium without FBS for 24 hours. After washing the cells once with PBS for UV irradiation, UVB 15 mJ / cm 2 was irradiated with 100 ⁇ l of PBS.
- the fresh medium without FBS was treated by diluting the final concentration of cumestrol to 0.01, 0.1, 1 ⁇ M.
- the expression of MMP-1 was evaluated. Expression of MMP-1 was collected using culture supernatants and evaluated using an enzyme-linked immunosorbent assay (ELISA) kit (RPN 2610; Biotrak Amersham Pharmacia Biotech, UK). The amount of was corrected to the total protein amount. The degree of MMP-1 activity (%) was calculated and shown in the table below.
- cumestrol has the effect of inhibiting the activity of UV-induced MMP-1, the higher the concentration of cumestrol, the higher the efficacy.
- a composition comprising cumestrol may inhibit collagen degradation to improve skin elasticity and wrinkles.
- human fibroblasts (CAS-C-004-5C, Invitrogen , CA, USA) to 24-well - one per well 1 X 10 4 to approximately 80 divides the plate It was incubated for about 24 hours in a medium containing 10% FBS until reaching% confluency. The fresh medium without FBS was treated with dilution so that the final concentration of cumestrol was 0.01, 0.1, 1 ⁇ M.
- Type I pN collagen synthesis was measured using a procollagen type I C-peptide (PIP) EIA kit (MK101; Takara Shuzo, Kyoto, Japan). .
- PIP procollagen type I C-peptide
- compositions comprising cumestrol may improve skin elasticity and wrinkles.
- human fibroblasts (CAS-C-004-5C, Invitrogen, Calif., USA) were dispensed at 6 x 6 plates at 5 X 10 4 per well. It was incubated for about 24 hours in a medium containing 10% FBS until reaching 80% confluency. After washing the cells once with PBS for UV irradiation, UVB 50 mJ / cm 2 was irradiated with 100 ⁇ l of PBS. After the removal of PBS, the fresh medium without FBS was treated by diluting to a final concentration of cumestrol to 2.5 ⁇ M.
- cumestrol inhibits glycation of skin cells.
- a composition comprising cumestrol may improve skin elasticity and exhibit skin whitening effects.
- a composition comprising cumestrol may promote energy metabolism of skin cells and activate skin cells to promote skin regeneration and improve skin elasticity.
- DMEM Dulbeccos modified Eagles media
- fetal placental serum 100 nM 2-O-tetradecanoyphorbol-13-acetate
- 1 nM cholera 1 nM cholera.
- the cultured Mel-Ab cells were detached with 0.25% trypsin-EDTA, incubated at a concentration of 10 5 cells / well in a 24-well plate incubator, and then 0.01, 0.1, 1 for 3 consecutive days from the second day. Incubated with addition of ⁇ M Kumethrol.
- the melanin production inhibition rate (%) was calculated based on the measured absorbance, and is shown in the following table.
- cumestrol is excellent in inhibiting melanin production.
- a composition comprising cumestrol may have an excellent skin lightening effect.
- prostaglandin E2 was quantified by lysing the cells and measuring absorbance at an ELISA reader 450 nm. . The results are shown in the table below. At this time, the inhibition rate (%) was calculated based on the difference between the production of prostaglandin E2 between the group treated with cumestrol and the group not treated with arachidonic acid, and the average value was calculated five times.
- cumestrol inhibits the production of prostaglandin E2. Therefore, the composition containing cumestrol has an anti-inflammatory effect and can further inhibit sebum secretion, alleviate skin troubles, and improve skin acne and skin allergy.
- cumestrol inhibits the biosynthesis of cyclooxygenase-2 induced by LPS.
- a composition comprising cumestrol may exhibit an anti-inflammatory effect and further improve skin acne and skin allergies.
- composition comprising cumestrol and cumestrol has the effect of improving atopic dermatitis.
- the amount of skin moisture loss of the test subject 9 was measured by a conniometer under constant temperature and humidity conditions (24 ° C., 40% relative humidity). The measurement results are averaged and shown in the table below.
- cumestrol inhibits skin moisture loss and its effect is greater over time.
- a composition comprising cumestrol may have a skin moisturizing effect.
- Nutritional creams are prepared by conventional methods according to the compositions set forth in the table below.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Cosmetics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
Abstract
Description
ROS 소거능 (%) | |
UV 대조군 | 0 |
쿠메스트롤 0.01 μM | 18.7 |
쿠메스트롤 0.1 μM | 25.6 |
쿠메스트롤 1 μM | 55.1 |
MMP-1 활성 (%) | |
무처리 대조군 | 100 |
UV 대조군 | 132 |
쿠메스트롤 0.01 μM | 115 |
쿠메스트롤 0.1 μM | 102 |
쿠메스트롤 1 μM | 98 |
타입 I pN 콜라겐 합성 정도(%) | |
무처리 대조군 | 100 |
쿠메스트롤 0.01 μM | 115 |
쿠메스트롤 0.1 μM | 126 |
쿠메스트롤 1 μM | 129 |
당화 최종 산물(㎍/ml) | |
무처리 대조군 | 0.156 |
쿠메스트롤 2.5 μM | 0.077 |
ATP 농도(nM) | |
무처리 대조군 | 803 |
쿠메스트롤 2.5 μM | 917 |
멜라닌 생성 억제율(%) | |
쿠메스트롤 0.01 μM | 1.2 |
쿠메스트롤 0.1 μM | 24.4 |
쿠메스트롤 1 μM | 30.1 |
하이드로퀴논 10 μM(양성 대조군) | 41.1 |
프로스타글란딘 E2 생성 억제율(%) | |
쿠메스트롤 0.01 μM | 12.8 |
쿠메스트롤 0.1 μM | 24.8 |
쿠메스트롤 1 μM | 38.2 |
COX-2 발현 정도(대조군 대비 %) | |
쿠메스트롤 0.01 μM | 89 |
쿠메스트롤 0.1 μM | 81 |
쿠메스트롤 1 μM | 64 |
해당 대상자 수(인) | ||||
현저히 개선 | 개선 | 변화 없음 | 악화 | |
대조군 | 1 | 4 | 8 | 2 |
쿠메스트롤 0.1% | 5 | 8 | 2 | 0 |
피부 수분 손실율 (%) | ||||
1주 경과 | 4주 경과 | 8주 경과 | 12주 경과 | |
대조군 | 34 | 39 | 41 | 36 |
쿠메스트롤 0.1% | 30 | 32 | 26 | 15 |
배합 성분 | 함량(중량 %) |
쿠메스트롤 | 1.0 |
글리세린 | 3.0 |
부틸렌글리콜 | 2.0 |
프로필렌글리콜 | 2.0 |
카르복시비닐폴리머 | 0.1 |
피이지-12 노닐페닐에테르 | 0.2 |
폴리솔베이트 80 | 0.4 |
에탄올 | 10.0 |
트리에탄올아민 | 0.1 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
배합 성분 | 함량(중량 %) |
쿠메스트롤 | 2.0 |
글리세린 | 3.0 |
부틸렌글리콜 | 3.0 |
프로필렌글리콜 | 3.0 |
카르복시비닐폴리머 | 0.1 |
밀납 | 4.0 |
폴리솔베이트 60 | 1.5 |
카프릴릭/카프릭 트리글리세라이드 | 5.0 |
스쿠알란 | 5.0 |
솔비타세스퀴올레이트 | 1.5 |
유동파라핀 | 0.5 |
세테아릴 알코올 | 1.0 |
트리에탄올아민 | 0.2 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
배합 성분 | 함량 (중량 %) |
쿠메스트롤 | 3.0 |
글리세린 | 3.0 |
부틸렌글리콜 | 3.0 |
유동파라핀 | 7.0 |
베타글루칸 | 7.0 |
카보머 | 0.1 |
카프릴릭/카프릭 트리글리세라이드 | 3.0 |
스쿠알란 | 5.0 |
세테아릴 글루코사이드 | 1.5 |
소르비탄 스테아레이트 | 0.4 |
폴리솔베이트 60 | 1.2 |
트리에탄올아민 | 0.1 |
방부제, 색소, 향료 | 적량 |
정제수 | 잔량 |
Claims (11)
- 쿠메스트롤; 또는 쿠메스트롤을 포함하는 콩 추출물을 포함하는 피부 미용용 조성물.
- 제 1 항에 있어서,피부 미용용 조성물은 피부 탄력 개선용 또는 주름 개선용인 피부 미용용 조성물.
- 제 1 항에 있어서,피부 미용용 조성물은 피부 미백용인 피부 미용용 조성물.
- 제 1 항에 있어서,피부 미용용 조성물은 피부 보습용인 피부 미용용 조성물.
- 제 1 항에 있어서,피부 미용용 조성물은 항염증용 또는 항균용인 피부 미용 조성물.
- 제 1 항에 있어서,피부 미용용 조성물은 피부 노화 억제용 또는 항산화용인 피부 미용용 조성물.
- 제 1 항에 있어서,피부 미용용 조성물은 여드름 피부 개선용인 피부 미용용 조성물.
- 제 1 항에 있어서,피부 미용용 조성물은 아토피 피부염 개선용인 피부 미용용 조성물.
- 제 1 항에 있어서,피부 미용용 조성물은 피부 자극 완화용 또는 피부 항상성 유지용인 피부 미용용 조성물.
- 제 1 항에 있어서,피부 미용용 조성물은 피부 알러지 완화 또는 개선용인 피부 미용용 조성물.
- 제 1 항 내지 제 10 항 중 어느 한 항에 있어서, 피부 미용용 조성물은 화장료 조성물인 피부 미용용 조성물.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2011800263374A CN102905685A (zh) | 2010-03-31 | 2011-03-31 | 含有香豆雌酚或包含香豆雌酚的豆提取物的、用于皮肤护理的化妆品组合物 |
US13/637,959 US9265707B2 (en) | 2010-03-31 | 2011-03-31 | Cosmetic composition comprising coumestrol or a bean extract containing coumestrol for skin care |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20100029164 | 2010-03-31 | ||
KR10-2010-0029164 | 2010-03-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011122869A2 true WO2011122869A2 (ko) | 2011-10-06 |
WO2011122869A3 WO2011122869A3 (ko) | 2012-02-02 |
Family
ID=44720419
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2011/002218 WO2011122869A2 (ko) | 2010-03-31 | 2011-03-31 | 쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물을 포함하는 피부 미용용 조성물 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9265707B2 (ko) |
KR (3) | KR20110110052A (ko) |
CN (3) | CN105362151A (ko) |
WO (1) | WO2011122869A2 (ko) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101854158B1 (ko) * | 2011-10-24 | 2018-06-14 | (주)아모레퍼시픽 | 콩꽃 추출물을 함유하는 피부 외용제 조성물 |
KR102063686B1 (ko) * | 2012-01-02 | 2020-02-11 | (주)아모레퍼시픽 | 콩뿌리 추출물을 함유하는 피부 외용제 조성물 |
KR101957845B1 (ko) * | 2012-07-31 | 2019-03-14 | (주)아모레퍼시픽 | 콩뿌리 추출물을 포함하는 모발 및 두피 상태 개선용 조성물 |
KR102014960B1 (ko) * | 2012-07-31 | 2019-08-28 | (주)아모레퍼시픽 | 콩뿌리 추출물을 함유하는 항산화용 조성물 |
KR102033448B1 (ko) * | 2012-07-31 | 2019-10-17 | (주)아모레퍼시픽 | 콩뿌리 추출물을 포함하는 항염증용 조성물 |
KR102014962B1 (ko) * | 2012-08-02 | 2019-08-28 | (주)아모레퍼시픽 | 콩꼬투리 추출물을 포함하는 항염증용 조성물 |
KR101985356B1 (ko) * | 2012-08-03 | 2019-06-04 | (주)아모레퍼시픽 | 발효콩 추출물을 함유하는 피부 외용제 조성물 |
KR101989067B1 (ko) * | 2013-02-28 | 2019-06-14 | (주)아모레퍼시픽 | 쿠메스트린을 함유하는 조성물 |
KR102200014B1 (ko) | 2013-05-06 | 2021-01-08 | (주)아모레퍼시픽 | 쿠메스트롤을 포함하는 콩 추출물을 유효성분으로 포함하는 갱년기 증상의 예방 및 치료용 조성물 |
WO2015018631A1 (en) * | 2013-08-09 | 2015-02-12 | Unilever N.V. | Skin care composition |
FR3015526B1 (fr) * | 2013-12-20 | 2017-02-17 | Oreal | Biomarqueur npy1r du lentigo actinique |
US9730972B1 (en) * | 2016-06-13 | 2017-08-15 | Ashley Diana Black International Holdings, Llc | Skin tightening lotion |
US20190134129A1 (en) | 2017-11-06 | 2019-05-09 | Sinotai Oncology Associate., Ltd. | Method for alleviating ultraviolet damage with ethyl acetate-extracted product of sedum formosanum |
KR102226151B1 (ko) * | 2017-11-20 | 2021-03-11 | (주)아모레퍼시픽 | 콩과식물 배양근을 이용한 쿠메스트롤 생산 방법 |
KR20200040583A (ko) * | 2018-10-10 | 2020-04-20 | (주)아모레퍼시픽 | 코티존 환원효소 저해용 조성물 |
KR102249711B1 (ko) * | 2018-10-23 | 2021-05-10 | (주)아모레퍼시픽 | 콩과 식물 배양근의 효소 처리 추출물을 함유하는 피부 탄력 증진용 또는 피부 주름 개선용 조성물 |
KR101997033B1 (ko) * | 2018-11-19 | 2019-07-08 | (주)아모레퍼시픽 | 콩뿌리 추출물을 포함하는 항염증용 조성물 |
CN116270281A (zh) * | 2023-04-14 | 2023-06-23 | 太和康美(北京)中医研究院有限公司 | 抑制油脂分泌的组合物及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020000980A (ko) * | 2000-06-23 | 2002-01-09 | 임병철 | 페룰산에스테르 유도체, 3,9-디페룰릴쿠메스트롤 및 이를함유한 화장료 |
JP2002516983A (ja) * | 1998-03-30 | 2002-06-11 | ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | 核受容体活性を調節するための方法及び化合物 |
US20050137176A1 (en) * | 2003-12-22 | 2005-06-23 | L'oreal | Use of a steroidal or non-steroidal EcR receptor ligand in a cosmetic or dermatological preparation for maintaining cutaneous homeostasis |
US20080107776A1 (en) * | 2006-11-02 | 2008-05-08 | The Coca-Cola Company | High-Potency Sweetener Composition With Phytoestrogen and Compositions Sweetened Therewith |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06321763A (ja) | 1993-05-17 | 1994-11-22 | Kao Corp | 美白剤 |
KR100628518B1 (ko) | 2003-06-12 | 2006-09-26 | 김홍렬 | 대두황권 추출물 및 이를 함유하는 피부노화 방지용기능성 화장품 |
ZA200609927B (en) * | 2004-05-28 | 2008-07-30 | Unigen Pharmaceuticals Inc | Diarylalkanes as potent inhibitors of binuclear enzymes |
KR20080018624A (ko) * | 2006-08-25 | 2008-02-28 | 제노마인(주) | 유기 셀레늄이 강화된 발아콩 추출물의 용도 |
KR100902326B1 (ko) * | 2007-07-27 | 2009-06-12 | 주식회사 엘지생활건강 | 발아콩 추출물을 포함하는 조성물 |
-
2011
- 2011-03-31 CN CN201510909598.0A patent/CN105362151A/zh active Pending
- 2011-03-31 US US13/637,959 patent/US9265707B2/en active Active
- 2011-03-31 CN CN201410243191.4A patent/CN103989589B/zh active Active
- 2011-03-31 WO PCT/KR2011/002218 patent/WO2011122869A2/ko active Application Filing
- 2011-03-31 CN CN2011800263374A patent/CN102905685A/zh active Pending
- 2011-03-31 KR KR1020110029582A patent/KR20110110052A/ko active Application Filing
-
2014
- 2014-03-12 KR KR1020140028981A patent/KR20140040790A/ko active Application Filing
-
2015
- 2015-08-20 KR KR1020150117315A patent/KR101677254B1/ko active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002516983A (ja) * | 1998-03-30 | 2002-06-11 | ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア | 核受容体活性を調節するための方法及び化合物 |
KR20020000980A (ko) * | 2000-06-23 | 2002-01-09 | 임병철 | 페룰산에스테르 유도체, 3,9-디페룰릴쿠메스트롤 및 이를함유한 화장료 |
US20050137176A1 (en) * | 2003-12-22 | 2005-06-23 | L'oreal | Use of a steroidal or non-steroidal EcR receptor ligand in a cosmetic or dermatological preparation for maintaining cutaneous homeostasis |
US20080107776A1 (en) * | 2006-11-02 | 2008-05-08 | The Coca-Cola Company | High-Potency Sweetener Composition With Phytoestrogen and Compositions Sweetened Therewith |
Also Published As
Publication number | Publication date |
---|---|
US20130071342A1 (en) | 2013-03-21 |
US9265707B2 (en) | 2016-02-23 |
CN102905685A (zh) | 2013-01-30 |
KR20140040790A (ko) | 2014-04-03 |
KR101677254B1 (ko) | 2016-11-17 |
WO2011122869A3 (ko) | 2012-02-02 |
KR20150101980A (ko) | 2015-09-04 |
CN103989589B (zh) | 2018-08-21 |
KR20110110052A (ko) | 2011-10-06 |
CN103989589A (zh) | 2014-08-20 |
CN105362151A (zh) | 2016-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2011122869A2 (ko) | 쿠메스트롤 또는 쿠메스트롤을 포함하는 콩 추출물을 포함하는 피부 미용용 조성물 | |
WO2020060060A1 (ko) | 병풀 부정근 추출물을 유효성분으로 함유하는 피부 미백 및 주름개선용 화장료 조성물 | |
WO2015053460A1 (ko) | 인삼열매 아위버섯 발효액을 함유하는 화장료 조성물 | |
KR101382112B1 (ko) | 편백다당체를 함유하는 피부 외용제 조성물 | |
WO2018111042A2 (ko) | 한약재 추출물을 유효성분으로 포함하는 화장료 조성물 | |
KR100742267B1 (ko) | 서장채국화 추출물, 이의 제조 방법 및 이를 유효성분으로 함유하는 미백용 화장료 조성물 | |
WO2013077569A1 (ko) | 흰감국 추출물을 함유하는 피부 외용제 조성물 | |
WO2016010283A1 (ko) | 납떼기콩 오일을 포함하는 조성물 | |
KR100848800B1 (ko) | 브라질리안 페퍼 오일을 함유하는 피부용 조성물 | |
KR100602684B1 (ko) | 망초 추출물을 유효성분으로 함유하는 미백용 화장료조성물 | |
BR102014025813A2 (pt) | composições compreendendo extratos de madeira de paulownia tomentosa e usos das mesmas | |
KR20150112103A (ko) | 식물추출물 또는 이의 분획물을 유효성분으로 함유하는 피부 상태 개선용 조성물 | |
WO2013115456A1 (ko) | 생강 초임계 추출물 및 발효 미나리 박 추출물을 함유하는 식품, 화장료 또는 약학 조성물 | |
KR20130022476A (ko) | 더위지기 추출물을 함유하는 화장료 조성물 | |
KR102525579B1 (ko) | 쌀, 갈대, 옥촉서예, 당아욱 및 알로에추출물을 포함하는 피부 보호용 화장료 조성물 | |
US20150104426A1 (en) | Skin-care agent containing pleurotus ferulae fruit body extract or pleurotus ferulae mycelium extract | |
KR20170045927A (ko) | 위릉채 추출물을 함유한 항노화 피부 외용제 조성물 및 그 제조방법 | |
WO2023008768A1 (ko) | 레코플라본 또는 이의 염을 포함하는 피부개선용 화장료 조성물 | |
WO2012115468A2 (ko) | 두부 순물을 포함하는 피부 미백용 조성물 | |
KR102561081B1 (ko) | 항염증, 항산화, 항균 및 피부 보습 효과를 갖는 화장료 조성물 | |
KR20130095949A (ko) | 진세노사이드 f1을 함유하는 피부 외용제 조성물 | |
KR20110062159A (ko) | 장뇌삼 캘러스 추출물을 함유하는 피부 미백용 화장료 조성물 | |
KR101877803B1 (ko) | 플로랄진세노사이드를 함유하는 피부 외용제 조성물 | |
KR101176522B1 (ko) | 복주머니란 추출물을 유효성분으로 함유하는 화장료 조성물 | |
WO2019216693A1 (ko) | 벌개미취 추출물 또는 이의 분획물을 포함하는 피부 미백용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180026337.4 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11763041 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13637959 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11763041 Country of ref document: EP Kind code of ref document: A2 |